Fundacio Ace Institut Catala De Neurociencies Aplicades — Clinical Trial Site

32 Registered trials

8 Currently recruiting

Organisation

Fundacio Ace Institut Catala De Neurociencies Aplicades

Location

Barcelona, Spain

Identifier

ORG-100042189

Address

Gran Via De Carles III 85 Bis, 08028, Spain

Departments

#40612:Neurology Department
Alzheimer Treatment & Research Center
Institut Catala de Neurocienies Aplicades
N/A
Neurología
Neurology
Unidad de valoración de la memoria y demencias

Clinical trials at this site (32)

Search interface

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease Ended

2023-506872-29-00 Alzheimer's Disease 4 2023-04-13
A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Particip… Ended

2023-504017-79-00 Treatment of AD dementia 4 2023-02-14
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the S… Ended

2024-511610-20-00 Alzheimer's Disease 4 2022-11-08
A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended

2023-506170-12-00 Alzheimer’s Disease 4 2021-10-18
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended

2023-506918-45-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended

2023-506919-18-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the … Ended

2022-501188-42-00 Early Alzheimer's Disease 4 2021-04-15
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in … Ended

2022-500691-59-00 Alzheimer's disease (AD) 4